DNA

#DNA #Gene therapy #Plasmid DNA #RNA

Yapan Bio expands to a new process development facility in India 

Yapan Bio has expanded its capabilities with a new process development facility at Genome Valley, Hyderabad, India, which has enhanced its ability to support end-to-end development and manufacturing of RNA, DNA and gene therapy products starting from plasmids.   The expansion includes three upstream suites (including Bio-Safety Level-2… Read More

#News

CRISPR gene editing
#CRISPR #CRISPR-Cas9 #DNA #Gene editing #Spherical nucleic acid

Gene editing platform could shape future application of CRISPR-based therapeutics

A team of researchers at Northwestern University in the US has devised a new platform for gene editing that could inform the future application of CRISPR-based therapeutics. Using chemical design and synthesis, the team brought together the Nobel-prize winning technology with therapeutic technology born in their own lab to overcome… Read More

#News

#DNA #Genetics / genomics

Up to 8 recipients to be awarded grants for genomic research

Beckman Coulter Life Sciences has released a call for registrations for its SPRI Grants for Genomic Research, which the company describes as part of its commitment to the next generation of researchers and scientists.  Reinforcing its dedication to providing streamlined genomic workflow solutions, the company will award… Read More

#News

#Biopharma #DNA #Drug discovery #Evonetix #Synthetic biology

Synthetic biology: Advancing drug discovery

This eBook, sponsored by Evonetix, contains exclusive insight from industry experts on how synthetic biology is innovating and advancing drug discovery.   Key topics include:   Four key approaches to synthetic biology  The global advances in synthetic biology drug discovery Why synthetic biology is the next big… Read More

#DDW eBooks

#DNA #Drug discovery #Gene sequencing #Synthetic biology

A different approach: reimagining biology

Listen to this article on the DDW Podcast: Evonetix is reimaging biology by developing a different approach to gene synthesis. Three key members of the team - Dr Raquel Sanches-Kuiper, Vice President of Technology, Dr Matthew Hayes, Chief Technology Officer and John Edgell, Head of Cloud Engineering – explain how the… Read More

#Exclusive Content

#Covid-19 #DNA #Drug discovery #Genomics #Infectious diseases

This week in drug discovery (18 -22 July)

News round-up by DDW’s Reece Armstrong for 18 – 22 July Covid-19 vaccines remain effective six months after second dose  Two doses of Covid-19 vaccines were sufficient in providing protection against severe cases of the infectious disease, according to new research.   New combination therapy… Read More

#News

#DNA #Institute of Cancer Research #Oncology

Junk DNA could lead to cancer, study says  

Non-coding or ‘junk’ DNA could contribute to the development of certain cancers due to how it disrupts the replication of the genome, scientists have discovered.   A team from The Institute of Cancer Research (ICR), London reconstituted the entire process of DNA replication in a test tube in… Read More

#News #Trending News

Back pain
#AstraZeneca #DNA #Oncology

Could this drug help repair nerve damage?  

Research from the University of Birmingham in the UK has indicated that a cancer therapy could help damaged nerves repair themselves following spinal injury.   The research shows that AstraZeneca’s candidate drug AZD1390 can block the response to DNA damage in nerve cells and promote regeneration of damaged… Read More

#News #Trending News

#Appointment #DNA #Synthetic biology

Evonetix appoints new CEO to support DNA platform  

Synthetic biology company Evonetix has appointed a new Chief Executive Officer (CEO) to support the company’s next phase of product development.   The company has appointed Colin McCracken as CEO with immediate effect. McCracken has over 20 years of experience and will support Evonetix in the development and… Read More

#News

#Biologics / Biotechnology #DNA

Evonetix gets patent for gene synthesis method  

Synthetic biology company Evonetix has been granted a European patent covering its unique Binary Assembly method for gene synthesis.  The patent forms part of the company’s plan to simplify gene synthesis for users and enable a new generation of in-lab DNA synthesis platforms.  Evonetix’s novel… Read More

#News

#Biochemistry #Biotechnology #DNA #Drug targets

New solution to accelerate repair genome editing research 

Integrated DNA Technologies (IDT) has released Alt-R HDR Donor Blocks, a solution for increasing homology-directed repair (HDR) rates in large fragment knock-in experiments.   How does Alt-R HDR work?  The Alt-R HDR Donor Blocks incorporate advanced chemical modifications to boost the HDR rates of large genomic… Read More

#News

#Biotechnology #DNA #Drug discovery #mRNA #Synthetic chemistry

From synthetic biology to synthesising DNA: helping advance research 

Evonetix is reimagining biology. Dr Vijay Narayan, Head of Physics, Dr Stuart Crosby, Head of Synthetic Chemistry, and Daniel Bygrave, Principal Software Engineer, offer insight into the technology being developed by the company and its relevance for researchers.  "I have always been intrigued by interdisciplinary environments,’ says Dr Vijay Narayan, Head of Physics, Evonetix. “This is… Read More

#Business & Investment #Editor's Choice #Exclusive Content #Intelligence #News #Trends & Analysis

CRISPR gene editing
#3D modelling #CRISPR #DNA #Drug discovery #Gene editing #Genomics #Screening

CRISPR screening in the third dimension 

Listen to this article on the DDW Podcast: Rosie Bryan & Carlos le Sage, Horizon Discovery, explain how CRISPR-Cas9 technology has become a gold standard for functional genomics.  While efforts in the cancer genomics field have uncovered the mutational landscapes in tumours covering many types of cancer, the functional contribution of the mutated… Read More

#Editor's Choice #Exclusive Content #News

#3D modelling #DNA #Drug development #Library screening #Screening

NovAliX enters partnership to design and screen new DNA-encoded libraries 

NovAliX, a CRO specialising in drug research and development, has partnered with Sanofi for the development of new DNA-Encoded Libraries (DELs), allowing the partners to design both general and focused chemical libraries, and carry out screening activities to identify new and useful chemical structures.  Why is this useful? … Read More

#News

#CAR-T #DNA #Drug development #Drug discovery #Podcast #Synthetic biology

Podcast: Building on current drug discovery methods

This is the latest episode of the free DDW podcast, “Building on current drug discovery methods”. It covers two narrated article written for Volume 22, Issue 2 – Spring 2021 of DDW and read aloud by Megan Thomas. The articles are called “The new synthesis: How synthetic DNA technology is… Read More

#News #Trending News